Nabriva strengthens board and management team
Mr. Rowland has over 30 years of diversified experience across a broad field of financial areas. Most recently, he was the Vice President and Chief Financial Officer of ViroPharma Inc., until its acquisition by Shire plc last year.
Prior to joining ViroPharma in 2008, Mr. Rowland was the Executive Vice President and Chief Financial Officer, as well as the interim Co-Chief Executive Officer, for Endo Pharmaceuticals Inc.
Prior roles include leadership positions at Biovail Corporation, Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland is a member of the board of directors and chairs the audit committee of Bind Therapeutics, Aurinia Pharmaceuticals and Vitae Pharmaceuticals. Previous board positions include Idenix Pharmaceuticals, Inc.
Mr. Rowland holds an M.B.A. with a finance concentration from Rutgers University and a Bachelor of Science in Accounting from Saint Joseph’s University. He is a Board Member of the Philadelphia chapter of Financial Executives International.
Dr. Gelone has been involved in all stages of drug development and commercialization for 20 years. Most recently he served as Head of Clinical Research and Development at Spark Therapeutics and was Vice President of Development at ViroPharma Inc. (which was acquired by Shire plc in January 2014).
Prior roles include leadership positions at GSK, Vicuron Pharmaceuticals and Temple University Schools of Pharmacy and Medicine. ■